Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 6/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.43 |
| ▸ | NNMT | P40261 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 2/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | OXTR | P30559 | 1/20 | 0.41 |
| ▸ | DAO | P14920 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4968773 | 0.88 | ACACB (0.50) | ACACBFFAR1NNMTPPARGPPARA | |
| SCHEMBL3861143 | 0.84 | ACACB (0.44) | ACACBFFAR1CPB2NNMTMEN1 | |
| SCHEMBL7945973 | 0.84 | ACACB (0.44) | ACACBFFAR1CPB2NNMTMEN1 | |
| SCHEMBL6262005 | 0.82 | ACACB (0.43) | ACACBFFAR1CPB2NNMTOXTR | |
| SCHEMBL10741906 | 0.82 | ACACB (0.40) | ACACBFFAR1CPB2NNMTOXTR | |
| SCHEMBL29852428 | 0.80 | KDM4E (0.52) | FFAR1CPB2PPARGMEN1KMT2A | |
| SCHEMBL8574971 | 0.79 | EPHX2 (0.51) | CPB2PPARGMEN1KMT2AEPHX2 | |
| SCHEMBL25213650 | 0.78 | KCNQ3 (0.47) | CPB2PPARGDAOEPHX2 | |
| SCHEMBL30469169 | 0.78 | KCNQ3 (0.47) | CPB2PPARGDAOEPHX2 | |
| SCHEMBL27956494 | 0.78 | JAK2 (0.45) | NNMTMEN1KMT2AKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1592421-A1 | HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS | Pharmacia Corporation (US) | 2005-11-09 | — | — | EP | disclosed |
| US-20050196557-A1 | Inkjet recording sheet, manufacturing method of inkjet recording sheet, and inkjet recording method | KONICA MINOLTA HOLDINGS, INC. | 2005-09-08 | — | — | US | disclosed |
| EP-1561593-A1 | Ink-jet recording sheet, its' manufacturing method, and ink-jet recording method | KONICA MINOLTA HOLDINGS, INC. (JP) | 2005-08-10 | — | — | EP | disclosed |
| US-20050043344-A1 | Heteroarylalkanoic acids as integrin receptor antagonists derivatives | PHARMACIA CORPORATION | 2005-02-24 | — | — | US | disclosed |
| WO-2004058254-A1 | HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS | PHARMACIA CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
| WO-2004058254-A1 | HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS | PHARMACIA CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043344-A1 | Heteroarylalkanoic acids as integrin receptor antagonists derivatives | ITGA5, ITGAV, ITGA6 | ACACB 2106/4885FFAR1 100/4885CPB2 2010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.